Clearmind Medicine (CMND) Change in Receivables (2022 - 2026)
Clearmind Medicine (CMND) posted quarterly Change in Receivables of -$22420.0 for Q2 2026, down 167.45% year-over-year from $33238.0 in Q2 2025, and up 72.75% quarter-over-quarter from -$82283.0 in Q1 2026.
Clearmind Medicine (CMND) Change in Receivables (2022 - 2026) Analysis & Trends
Clearmind Medicine's Change in Receivables history runs 5 years deep, the most recent figure standing at -$22420.0 for Q2 2026.
- In Q2 2026, Change in Receivables fell 167.45% year-over-year to -$22420.0; the TTM figure through Apr 2026 stood at -$93471.0 (down 8305.67% YoY), while the FY2025 annual figure was $17249.0, down 73.44% from the prior year.
- Change in Receivables for Q2 2026 stood at -$22420.0, up from -$82283.0 in the prior quarter.
- The five-year high for Change in Receivables was $82.8 billion in Q3 2022, with the low at -$82.8 billion in Q4 2022.
- The 5-year median for Change in Receivables is -$1071.0 (2023), against an average of -$3794.1.
- The sharpest annual moves came in 2023 and 2024: Change in Receivables slumped 752.66% in 2023, then jumped 1045.75% in 2024.
- Clearmind Medicine's Change in Receivables stood at -$82.8 billion in 2022, then surged by 100.0% to -$1071.0 in 2023, then surged by 1045.75% to $10129.0 in 2024, then sank by 80.99% to $1926.0 in 2025, then tumbled by 1264.07% to -$22420.0 in 2026.
- Business Quant data shows CMND's Change in Receivables at -$22420.0 in Q2 2026, -$82283.0 in Q1 2026, and $1926.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | - |
| 10 | Clearmind Medicine | 539,005.73 | -13.05 Mn | - | -22,420.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -22,420.00 |
| Apr 30, 2026 | -22,420.00 |
| Jan 31, 2026 | -82,283.00 |
| Jan 31, 2026 | -82,283.00 |
| Oct 31, 2025 | 1,926.00 |
| Oct 31, 2025 | 1,926.00 |
| Jul 31, 2025 | 9,306.00 |
| Jul 31, 2025 | 9,306.00 |
| Apr 30, 2025 | 33,238.00 |
| Apr 30, 2025 | 33,238.00 |
| Jan 31, 2025 | -27,221.00 |
| Jan 31, 2025 | -27,221.00 |
| Oct 31, 2024 | 10,129.00 |
| Oct 31, 2024 | 10,129.00 |
| Jul 31, 2024 | -17,258.00 |
| Jul 31, 2024 | -17,258.00 |
| Apr 30, 2024 | -21,494.00 |
| Apr 30, 2024 | -21,494.00 |
| Jan 31, 2024 | 93,572.00 |
| Jan 31, 2024 | 93,572.00 |